Big Bets Aim to Jolt Heart Drug Sales Back to Life
8/29/2012 8:22:40 AM
The expiry of patents on profitable heart medicines is soon going to erode one of the main sources of drug company profits, and risky bets on new medicines to replace them may not make up for the lost sales. High-octane salesmanship was still on show at giant trade stands during this week's European Society of Cardiology congress - the world's biggest heart meeting with 28,000 participants - but the razzmatazz hides a business in trouble.
comments powered by